国际妇产科学杂志

国际妇产科学杂志 ›› 2016, Vol. 43 ›› Issue (2): 135-139.

• 综述 • 上一篇    下一篇

贝伐单抗治疗晚期妇科恶性肿瘤

杜文静，董信芳，刘大江，杨永秀   

  1. 730000 兰州大学第一临床医学院（杜文静，刘大江），基础医学院（董信芳）；兰州大学第一医院妇产科（杨永秀）
  • 收稿日期:1900-01-01 修回日期:1900-01-01 出版日期:2016-04-15 发布日期:2016-04-15
  • 通讯作者: 杨永秀

Bevacizumab for Advanced Gynecological Cancer

DU Wen-jing，DONG Xin-fang，LIU Da-jiang，YANG Yong-xiu   

  1. The First Clinical Medical School（DU Wen-jing，LIU Da-jiang），The Basic Medical College（DONG Xin-fang），Lanzhou University，Lanzhou 730000，China；Department of Gynecology and Obstetrics，The First Hospital of Lanzhou University，Lanzhou 730000，China（YANG Yong-xiu）
  • Received:1900-01-01 Revised:1900-01-01 Published:2016-04-15 Online:2016-04-15
  • Contact: YANG Yong-xiu

PDF (PC)

5878

被引次数

2

摘要： 随着临床对恶性肿瘤研究的深入，分子靶向治疗成为继手术、放疗、化疗后的第4种用于治疗恶性肿瘤的新方法，因其具有特异性强、提高抗肿瘤作用、延长患者生存期的优点备受肿瘤研究者的关注。抗血管内皮生长因子（VEGF）抗体的靶向治疗越来越受重视，而贝伐单抗成为关注的焦点，其是一种重组人源化抗VEGF的单克隆抗体，可与肿瘤细胞上的VEGF特异性结合，而VEGF是肿瘤血管生长的关键调节因子，因此贝伐单抗可以抑制肿瘤血管的生长从而抑制肿瘤细胞的生长。目前，贝伐单抗已被美国食品和药物管理局批准用于卵巢癌、复发或转移性宫颈癌、结直肠癌、肺癌及肾癌的一线治疗。近年来，越来越多研究关注贝伐单抗作为一种新型治疗方法用于晚期妇科恶性肿瘤的治疗，就贝伐单抗在晚期妇科恶性肿瘤中的研究进展进行综述。

关键词: 生殖器肿瘤, 女（雌）性, 血管内皮生长因子类, 肿瘤治疗方案, 贝伐单抗

Abstract: As clinical researches for malignant tumors developing, molecular targeted therapy, following radical surgery, chemotherapy and radiotherapy, has become a novel and the 4th treatment for the advanced gynecological cancers. It also gathered more and more attention of cancer researchers due to its high level of specificity and abilities of enhance the effect of the anticancer, extension the survival period of patient. More and more attention has been attracted by molecular targeted therapy of anti VEGF antibody, and bevacizumab becomes the focus of attention. Bevacizumab is a monoclonal antibody that can specifically combine with VEGF, which is the key regulatory factor on the growth of tumor blood vessels. By the process mentioned above, bevacizumab can prevent VEGF from combining with its receptor, thus inhibit the formation of tumor blood vessels and achieve anticancer efficacy. At present, bevacizumab is acting as first-line medicine to treat ovarian cancer, recurrent or advanced metastatic cervical cancer, colorectal cancer, lung cancer and renal cell carcinoma which was approved by the Food and Drug Administration (FDA). Recently, treating advanced gynecological cancers with the use of bevacizumab, which is regarded as a novel therapeutic, becomes the focus of numerous studies. This paper reviews research progress in bevacizumab to treat advanced gynecological cancers.

Key words: Genital neoplasms, female, Vascular endothelial growth factors, Antineoplastic protocols, Bevacizumab